Biomarker for myalgic encephalomyelitis/chronic fatigue syndrome (me/cfs)
WO2020022362A1
Motion detection device, feature detection device, fluid detection device, motion detection system, motion detection method, program, and recording medium
WO2019189725A1
Neonatal hypoxic-ischemic encephalopathy severity determining method and prognosis predicting method
TW201945009A
An oligodendrocyte-specific promoter, a miRNA specific for the PLP1 gene, a vector containing the promotor and / or the miRNA, and a pharmaceutical composition containing the vector
WO2020136696A1
Method for inducing muscular cells using cells in spot urine
EP3620531A1
Method for predicting and evaluating therapeutic effect in diseases related to il-6 and neutrophils
EP3549607A1
Prophylactic agent, onset-suppressing agent or therapeutic agent for progressive immune demyelinating diseases
EP3527212A1
Myogenesis inducing agent
WO2017110705A1
Agent for enhancing synapse formation and therapeutic agent for neurodegenerative disease
WO2017034031A1
Autoimmune disease diagnosis method, autoimmune disease diagnosis biomarker, and autoimmune disease preventing or treating agent
US2018186887A1
Therapeutic agent for mental illness comprising il-6 inhibitor as active ingredient
US2018149573A1
Method for determining application of therapy to multiple sclerosis (MS) patient
EP3284830A1
Biomarker for mental disease
AU2015203659A1
Antisense nucleic acid
EP3144002A1
GM-CSF-PRODUCING T-CELL CONTROL AGENT AND Th1/Th2 IMMUNE BALANCE REGULATOR
AU2015227733A1
Antisense nucleic acids
EP3000878A1
Stem cells for transplantation and manufacturing method therefor
EP3777843A1
Drug delivery particle and method for producing the same
